A new solid target design for the production of Zr and radiosynthesis of high molar activity [Zr]Zr-DBN.

Due to the advent of various biologics like antibodies, proteins, cells, viruses, and extracellular vesicles as biomarkers for disease diagnosis, progression, and as therapeutics, there exists a need to have a simple and ready to use radiolabeling synthon to enable noninvasive imaging trafficking studies. Previously, we reported [Zr]zirconium--isothiocyanatobenzyl-desferrioxamine ([Zr]Zr-DBN) as a synthon for the radiolabeling of biologics to allow PET imaging of cell trafficking. In this study, we focused on improving the molar activity (A) of [Zr]Zr-DBN, by enhancing Zr production on a low-energy cyclotron and developing a new reverse phase HPLC method to purify [Zr]Zr-DBN.